LAMEA Hemophilia Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type (Hemophilia A, Hemophilia B), By Treatment Type (Prophylaxis, On-demand, and Cure), By Therapy, By Country and Growth Forecast, 2023 - 2030

The Latin America, Middle East and Africa Hemophilia Market would witness market growth of 12.1% CAGR during the forecast period (2023-2030).

The introduction of technologically sophisticated diagnostic tools and therapies to improve the efficacy and accuracy of hemophilia therapy is another focus of top industry players. Early diagnosis and better treatment of hemophilia have been made possible by increased knowledge of the disorder among patients and healthcare providers. As a result, more patients are being discovered and obtaining the proper care, which supports market expansion. Intravenous infusions are the main form of treatment, which involve adding extra clotting factor to the patient's blood. With bleeding diseases, surgeries are performed with extra caution. As a result, the patient's surgeon needs to be aware of this problem. It is also crucial to educate blood relatives about the issue because they can possibly develop the condition.

Due to greater awareness, improved healthcare infrastructure, and higher disposable incomes, the hemophilia market is expanding in emerging countries. Hemophilia medicines are increasingly being used in emerging economies, which is further fueling market expansion. Patient organizations and advocacy groups for hemophilia are essential in educating the public, assisting patients, and influencing healthcare regulations. Their efforts enhance people's access to resources and therapies, which has a favorable effect on the market.

Large families, advanced maternal and paternal ages, and consanguinity rates—the number of marriages between close relatives—commonly found in the Middle East and Africa region all play a key role in the higher occurrence of genetic and congenital disorders. In Saudi Arabia, congenital malformations account for a sizable part of perinatal deaths, and they rank second among the causes of infant mortality in Bahrain, Kuwait, Oman, and Qatar. Additionally, because of the burgeoning pharmaceutical industry in this region, there is a rising need for contemporary treatments. Because it is anticipated that regional pharmaceutical industry sales will rise over the coming few years, there is a significant probability that an investment will pay off. The need for hemophilia therapies will grow dramatically in this region during the next few years, driving the expansion of the market.

The Brazil market dominated the LAMEA Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $352.9 million by 2030. The Argentina market is showcasing a CAGR of 12.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 11.8% during (2023 - 2030).

Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Worldwide Hemophilia Market is Projected to reach USD 18.3 Billion by 2030, at a CAGR of 6.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

• Specialty Pharmacies
• Hospital Pharmacies

By Type

• Hemophilia A
• Hemophilia B
• Others

By Treatment Type

• Prophylaxis
• On-demand
• Cure

By Therapy

• Factor Replacement Therapy
  • Recombinant Factor Concentrates
  • Plasma-derived Factor Concentrates
• Desmopressin & Fibrin Sealants
• Gene Therapy & Monoclonal Antibodies

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Takeda Pharmaceutical Company Limited
• CSL Limited (CSL Behring)
• Pfizer, Inc.
• Bayer AG
• F.Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Octapharma AG
• BioMarin Pharmaceutical Inc.
• Swedish Orphan Biovitrum AB (Investor AB)
• Sanofi S.A.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Hemophilia Market, by Distribution Channel
1.4.2 LAMEA Hemophilia Market, by Type
1.4.3 LAMEA Hemophilia Market, by Treatment Type
1.4.4 LAMEA Hemophilia Market, by Therapy
1.4.5 LAMEA Hemophilia Market, by Country
1.5 Methodology for the research

Chapter 2. Market At a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
4.4 Porter Five Forces Analysis

Chapter 5. LAMEA Hemophilia Market by Distribution Channel
5.1 LAMEA Specialty Pharmacies Market by Country
5.2 LAMEA Hospital Pharmacies Market by Country

Chapter 6. LAMEA Hemophilia Market by Type
6.1 LAMEA Hemophilia A Market by Country
6.2 LAMEA Hemophilia B Market by Country
6.3 LAMEA Others Market by Country

Chapter 7. LAMEA Hemophilia Market by Treatment Type
7.1 LAMEA Prophylaxis Market by Country
7.2 LAMEA On-demand Market by Country
7.3 LAMEA Cure Market by Country

Chapter 8. LAMEA Hemophilia Market by Therapy
8.1 LAMEA Factor Replacement Therapy Market by Country
8.2 LAMEA Hemophilia Market by Factor Replacement Therapy Type
8.2.1 LAMEA Recombinant Factor Concentrates Market by Country
8.2.2 LAMEA Plasma-derived Factor Concentrates Market by Country
8.3 LAMEA Desmopressin & Fibrin Sealants Market by Country
8.4 LAMEA Gene Therapy & Monoclonal Antibodies Market by Country

Chapter 9. LAMEA Hemophilia Market by Country
9.1 Brazil Hemophilia Market
9.1.1 Brazil Hemophilia Market by Distribution Channel
9.1.2 Brazil Hemophilia Market by Type
9.1.3 Brazil Hemophilia Market by Treatment Type
9.1.4 Brazil Hemophilia Market by Therapy
9.1.4.1 Brazil Hemophilia Market by Factor Replacement Therapy Type
9.2 Argentina Hemophilia Market
9.2.1 Argentina Hemophilia Market by Distribution Channel
9.2.2 Argentina Hemophilia Market by Type
9.2.3 Argentina Hemophilia Market by Treatment Type
9.2.4 Argentina Hemophilia Market by Therapy
9.2.4.1 Argentina Hemophilia Market by Factor Replacement Therapy Type
9.3 UAE Hemophilia Market
9.3.1 UAE Hemophilia Market by Distribution Channel
9.3.2 UAE Hemophilia Market by Type
9.3.3 UAE Hemophilia Market by Treatment Type
9.3.4 UAE Hemophilia Market by Therapy
9.3.4.1 UAE Hemophilia Market by Factor Replacement Therapy Type
9.4 Saudi Arabia Hemophilia Market
9.4.1 Saudi Arabia Hemophilia Market by Distribution Channel
9.4.2 Saudi Arabia Hemophilia Market by Type
9.4.3 Saudi Arabia Hemophilia Market by Treatment Type
9.4.4 Saudi Arabia Hemophilia Market by Therapy
9.4.4.1 Saudi Arabia Hemophilia Market by Factor Replacement Therapy Type
9.5 South Africa Hemophilia Market
9.5.1 South Africa Hemophilia Market by Distribution Channel
9.5.2 South Africa Hemophilia Market by Type
9.5.3 South Africa Hemophilia Market by Treatment Type
9.5.4 South Africa Hemophilia Market by Therapy
9.5.4.1 South Africa Hemophilia Market by Factor Replacement Therapy Type
9.6 Nigeria Hemophilia Market
9.6.1 Nigeria Hemophilia Market by Distribution Channel
9.6.2 Nigeria Hemophilia Market by Type
9.6.3 Nigeria Hemophilia Market by Treatment Type
9.6.4 Nigeria Hemophilia Market by Therapy
9.6.4.1 Nigeria Hemophilia Market by Factor Replacement Therapy Type
9.7 Rest of LAMEA Hemophilia Market
9.7.1 Rest of LAMEA Hemophilia Market by Distribution Channel
9.7.2 Rest of LAMEA Hemophilia Market by Type
9.7.3 Rest of LAMEA Hemophilia Market by Treatment Type
9.7.4 Rest of LAMEA Hemophilia Market by Therapy
9.7.4.1 Rest of LAMEA Hemophilia Market by Factor Replacement Therapy Type

Chapter 10. Company Profiles
10.1 Swedish Orphan Biovitrum AB (Investor AB)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Takeda Pharmaceutical Company Limited
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Trials and Approvals:
10.2.5.2 Product Launches and Product Expansions:
10.3 Pfizer, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional & Segmental Analysis
10.3.4 Research & Development Expense
10.3.4.1 Partnerships, Collaborations, and Agreements:
10.3.4.2 Acquisition and Mergers:
10.4 CSL Limited (CSL Behring)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Trials and Approvals:
10.4.5.2 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Octapharma AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Research & Development Expenses
10.5.4 Recent strategies and developments:
10.5.4.1 Trials and Approvals:
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.6.5.2 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 SWOT Analysis
10.8 Novo Nordisk A/S
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental & Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Product Launches and Product Expansions:
10.8.5.3 Acquisition and Mergers:
10.8.6 SWOT Analysis
10.9 BioMarin Pharmaceutical Inc.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Trials and Approvals:
10.9.6 SWOT Analysis
10.10. Sanofi S.A.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Trials and Approvals:

TABLE 1 LAMEA Hemophilia Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Hemophilia Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Hemophilia Market
TABLE 4 Product Launches And Product Expansions– Hemophilia Market
TABLE 5 Acquisition and Mergers– Hemophilia Market
TABLE 6 Trials and Approvals– Hemophilia Market
TABLE 7 LAMEA Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 LAMEA Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 LAMEA Specialty Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Specialty Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 LAMEA Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 LAMEA Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 14 LAMEA Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 15 LAMEA Hemophilia A Market by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Hemophilia A Market by Country, 2023 - 2030, USD Million
TABLE 17 LAMEA Hemophilia B Market by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Hemophilia B Market by Country, 2023 - 2030, USD Million
TABLE 19 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 21 LAMEA Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 22 LAMEA Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 23 LAMEA Prophylaxis Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Prophylaxis Market by Country, 2023 - 2030, USD Million
TABLE 25 LAMEA On-demand Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA On-demand Market by Country, 2023 - 2030, USD Million
TABLE 27 LAMEA Cure Market by Country, 2019 - 2022, USD Million
TABLE 28 LAMEA Cure Market by Country, 2023 - 2030, USD Million
TABLE 29 LAMEA Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 30 LAMEA Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 31 LAMEA Factor Replacement Therapy Market by Country, 2019 - 2022, USD Million
TABLE 32 LAMEA Factor Replacement Therapy Market by Country, 2023 - 2030, USD Million
TABLE 33 LAMEA Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 34 LAMEA Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 35 LAMEA Recombinant Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 36 LAMEA Recombinant Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 37 LAMEA Plasma-derived Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 38 LAMEA Plasma-derived Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 39 LAMEA Desmopressin & Fibrin Sealants Market by Country, 2019 - 2022, USD Million
TABLE 40 LAMEA Desmopressin & Fibrin Sealants Market by Country, 2023 - 2030, USD Million
TABLE 41 LAMEA Gene Therapy & Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 42 LAMEA Gene Therapy & Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 43 LAMEA Hemophilia Market by Country, 2019 - 2022, USD Million
TABLE 44 LAMEA Hemophilia Market by Country, 2023 - 2030, USD Million
TABLE 45 Brazil Hemophilia Market, 2019 - 2022, USD Million
TABLE 46 Brazil Hemophilia Market, 2023 - 2030, USD Million
TABLE 47 Brazil Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 Brazil Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 49 Brazil Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 50 Brazil Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 51 Brazil Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 52 Brazil Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 53 Brazil Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 54 Brazil Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 55 Brazil Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 56 Brazil Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 57 Argentina Hemophilia Market, 2019 - 2022, USD Million
TABLE 58 Argentina Hemophilia Market, 2023 - 2030, USD Million
TABLE 59 Argentina Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 60 Argentina Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 61 Argentina Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 62 Argentina Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 63 Argentina Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 64 Argentina Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 65 Argentina Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 66 Argentina Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 67 Argentina Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 68 Argentina Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 69 UAE Hemophilia Market, 2019 - 2022, USD Million
TABLE 70 UAE Hemophilia Market, 2023 - 2030, USD Million
TABLE 71 UAE Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 72 UAE Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 73 UAE Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 74 UAE Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 75 UAE Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 76 UAE Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 77 UAE Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 78 UAE Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 79 UAE Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 80 UAE Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 81 Saudi Arabia Hemophilia Market, 2019 - 2022, USD Million
TABLE 82 Saudi Arabia Hemophilia Market, 2023 - 2030, USD Million
TABLE 83 Saudi Arabia Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 84 Saudi Arabia Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 85 Saudi Arabia Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 86 Saudi Arabia Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 87 Saudi Arabia Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 88 Saudi Arabia Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 89 Saudi Arabia Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 90 Saudi Arabia Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 91 Saudi Arabia Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 92 Saudi Arabia Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 93 South Africa Hemophilia Market, 2019 - 2022, USD Million
TABLE 94 South Africa Hemophilia Market, 2023 - 2030, USD Million
TABLE 95 South Africa Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 96 South Africa Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 97 South Africa Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 98 South Africa Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 99 South Africa Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 100 South Africa Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 101 South Africa Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 102 South Africa Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 103 South Africa Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 104 South Africa Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 105 Nigeria Hemophilia Market, 2019 - 2022, USD Million
TABLE 106 Nigeria Hemophilia Market, 2023 - 2030, USD Million
TABLE 107 Nigeria Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 108 Nigeria Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 109 Nigeria Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 110 Nigeria Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 111 Nigeria Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 112 Nigeria Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 113 Nigeria Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 114 Nigeria Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 115 Nigeria Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 116 Nigeria Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 117 Rest of LAMEA Hemophilia Market, 2019 - 2022, USD Million
TABLE 118 Rest of LAMEA Hemophilia Market, 2023 - 2030, USD Million
TABLE 119 Rest of LAMEA Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 120 Rest of LAMEA Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 121 Rest of LAMEA Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 122 Rest of LAMEA Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 123 Rest of LAMEA Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 124 Rest of LAMEA Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 125 Rest of LAMEA Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 126 Rest of LAMEA Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 127 Rest of LAMEA Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 128 Rest of LAMEA Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 129 Key Information – Swedish Orphan Biovitrum AB
TABLE 130 Key Information – Takeda Pharmaceutical Company Limited
TABLE 131 Key Information – Pfizer, Inc.
TABLE 132 Key Information – CSL Limited
TABLE 133 Key Information – Octapharma AG
TABLE 134 Key Information – Bayer AG
TABLE 135 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 136 Key Information – Novo Nordisk A/S
TABLE 137 Key Information – BioMarin Pharmaceutical Inc.
TABLE 138 Key Information – Sanofi S.A.

List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Hemophilia Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Hemophilia Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis –Hemophilia Market
FIG 8 LAMEA Hemophilia Market share by Distribution Channel, 2022
FIG 9 LAMEA Hemophilia Market share by Distribution Channel, 2030
FIG 10 LAMEA Hemophilia Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 LAMEA Hemophilia Market share by Type, 2022
FIG 12 LAMEA Hemophilia Market share by Type, 2030
FIG 13 LAMEA Hemophilia Market by Type, 2019 - 2030, USD Million
FIG 14 LAMEA Hemophilia Market share by Treatment Type, 2022
FIG 15 LAMEA Hemophilia Market share by Treatment Type, 2030
FIG 16 LAMEA Hemophilia Market by Treatment Type, 2019 - 2030, USD Million
FIG 17 LAMEA Hemophilia Market share by Therapy, 2022
FIG 18 LAMEA Hemophilia Market share by Therapy, 2030
FIG 19 LAMEA Hemophilia Market by Therapy, 2019 - 2030, USD Million
FIG 20 LAMEA Hemophilia Market share by Country, 2022
FIG 21 LAMEA Hemophilia Market share by Country, 2030
FIG 22 LAMEA Hemophilia Market by Country, 2019 - 2030, USD Million
FIG 23 SWOT Analysis: Swedish Orphan Biovitrum AB
FIG 24 SWOT Analysis: CSL Limited
FIG 25 SWOT Analysis: Octapharma AG
FIG 26 SWOT Analysis: Bayer AG
FIG 27 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 28 Recent strategies and developments: Novo Nordisk A/S
FIG 29 SWOT Analysis: Novo Nordisk A/S
FIG 30 SWOT Analysis: BioMarin Pharmaceutical Inc.